Bristol-Myers Squibb (NYSE:BMY) Receives Underweight Rating from Morgan Stanley

Morgan Stanley restated their underweight rating on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $59.00 price target on the biopharmaceutical company’s stock. BMY has been the subject of several other reports. 51job restated a maintains rating on shares of Bristol-Myers Squibb […]

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Pomalyst Imnovid ,Rupert Vessey ,Bristol Myers Squibb ,Advisors Inc ,Morgan Stanley ,Baron Silver Stevens Financial Advisors ,Bristol Myers Squibb Company Profile ,Atlas Wealth ,Talbot Financial ,Securities Exchange Commission ,Bristol Myers Squibb Company ,Free Report ,Capital Markets ,Myers Squibb ,Get Free Report ,Exchange Commission ,Portfolio Management ,Silver Stevens Financial Advisors ,Myers Squibb Company ,Bristol Myers Squibb Daily ,Nyse Bmy ,Bmy ,Medical ,11012210 ,Reiterated Rating ,